PRECOS partners with Reliable Cancer Therapies

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has signed a partnership agreement with Reliable Cancer Therapies (RCT) to provide scientific validation of existing data for cancer therapies. The partnership will see PRECOS provide drug efficacy work to support RCT’s research on complementary medicines, so that evidence-based treatment choices can be made with confidence by patients and health professionals.

RCT is a Swiss private non-profit organisation dedicated to selectively funding the development of, and providing research-based information on, promising cancer therapies. Rigorous scientific research is required for any medical therapy for ethical and safety reasons and this also applies to therapies that use herbs, vitamins, minerals and other natural substances.

Comprehensive research into complementary medicine is vital to ensure efficacy, safety, quality and cost-effectiveness of new therapies.

As a world leader in the provision of pre-clinical research and development services for oncology drug discovery, PRECOS evaluates oncology therapies for major pharmaceutical and biotech companies worldwide. As a result, the company is ideally placed to apply its proven scientific expertise to RCT’s projects. This partnership will see PRECOS validate RCT’s existing research using PRECOS’s unique expertise in validated patient relevant cancer models which includes in vitro 2D and 3D assays, in vivo therapeutic evaluations and post-study analyses on for example a total herbal extract to evaluate product efficacy and scientific validation.

“There is a need for reliable data of non-conventional cancer treatments,” said Luc Verelst, founder of RCT. “The majority of the research conducted to date is not sufficiently scientifically or statistically rigorous to prove the benefits of these therapies. It is crucial for RCT to partner with a company with such a strong scientific reputation like PRECOS. With the support of such an innovative organisation in the oncology arena this situation can be improved and reliable, high quality scientific evidence can be provided.”

Dr. Neil Rotherham, chairman of the PRECOS board highlights: “Our advanced models challenge new therapeutic agents similar to the situation in the patient thereby providing more relevant and clinically predictive data which we have applied to a broad spectrum of therapies including complementary therapies. We are therefore well positioned to support RCT in such an exciting area of research.” Neil continues, “We are very excited to partner with RCT and to be able to provide robust scientific data for the evaluation of promising complementary cancer therapies. PRECOS is proud of our scientific expertise and are happy to be able to apply our innovative technologies to advance cancer treatment and care in any way possible, whether that is conventional or non-conventional cancer treatments.”

For more information on PRECOS, please call +44 (0)870 166 6234, email [email protected] or visit www.precos.co.uk

For more information on RCT, email [email protected] or visit www.reliablecancertherapies.com